This study was conducted to determine the effects of either dietary Se source or dose on the Se status of horses. Twenty-five mature horses were blocked by BW and randomly allocated to 1 of 5 dietary treatments that comprised the same basal diet that differed only in Se source or dose. Treatments were as follows: negative control (0.085 mg of Se/kg of DM), 3 different dietary concentrations of supplemental organic Se (Se yeast; 0.2, 0.3, and 0.4 mg of total Se/kg of DM), and positive control (0.3 mg of total Se/kg of DM) supplemented with Na selenite. Horses initially received the control diet (6 kg of grass hay and 3 kg of concentrate per horse daily) for 56 d to allow diet adaptation. After the period of diet adaptation, horses were offered their respective treatments for a continuous period of 112 d. Jugular venous blood samples were collected before the morning feed on d 0, 28, 56, 84, and 112. Whole blood and plasma were analyzed for total Se, glutathione peroxidase activity in whole blood (GPX-1) and plasma, and thyroid hormones (thyroxine and triiodothyronine) in plasma. The proportion of total Se as selenomethionine (SeMet) or selenocysteine in pooled whole blood and plasma samples was determined on d 0, 56, and 112. Data were analyzed as repeated measures. Total Se in blood and plasma and GPX-1 activity were greater in all supplemented horses (P < 0.001, except P < 0.01 for GPX-1 in horses supplemented with the least dose of Se yeast) with a linear dose effect of Se yeast for whole blood and plasma Se (P < 0.001) and a quadratic dose effect (P < 0.05) for whole blood GPX-1 activity. A plateau for total Se in plasma was achieved within 75 to 90 d, although this was not observed in blood total Se or GPX-1 activity. On d 84 and 112, horses supplemented with Se yeast showed greater total Se in blood (P < 0.05) compared with horses supplemented with Na selenite, and a source effect (P < 0.05) was observed in the relationship between total blood Se and GPX-1 activity. Selenocysteine (the predominant form of Se in whole blood and plasma) increased in all horses supplemented with Se. The SeMet content of whole blood and plasma increased in horses supplemented with Se yeast, but it was not observed in those supplemented with selenite. The rate of increase in SeMet over time was greater in whole blood (P < 0.05) and plasma (P = 0.10) with the Se yeast product. In conclusion, Se yeast was more effective than Na selenite in increasing total Se in blood, mainly as consequence of a greater increase of the proportion of Se comprised as SeMet, but it did not modify GPX-1 activity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2527/jas.2007-0746 | DOI Listing |
Blood Adv
January 2025
Mayo Clinic, Rochester, Minnesota, United States.
In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3,487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs.
View Article and Find Full Text PDFBlood Adv
January 2025
Vanderbilt University Medical Center, Nashville, Tennessee, United States.
In plasma, the zymogens factor XII (FXII) and prekallikrein reciprocally convert each other to the proteases FXIIa and plasma kallikrein (PKa). PKa cleaves high-molecular-weight kininogen (HK) to release bradykinin, which contributes to regulation of blood vessel tone and permeability. Plasma FXII is normally in a "closed" conformation that limits activation by PKa.
View Article and Find Full Text PDFAm Soc Clin Oncol Educ Book
January 2025
Division of Oncology, Department of Medicine, University of Washington, Seattle, WA.
The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB urothelial carcinoma have molecular analysis that integrates at least testing to help facilitate the selection of future therapeutic options. Sequencing of tumor-derived tissue is the mainstay to obtain this genomic testing, but as in other cancers, there has been extensive research into the integration of liquid biopsies in longitudinal management.
View Article and Find Full Text PDFJ Leukoc Biol
January 2025
Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA.
Regulated sequential exocytosis of neutrophil granules is essential in orchestrating the innate immune response, while uncontrolled secretion causes inflammation. We developed and characterized Nexinhib20, a small-molecule inhibitor that targets azurophilic granule exocytosis in neutrophils by blocking the interaction between the small GTPase Rab27a and its effector JFC1. Its therapeutic potential has been demonstrated in several pre-clinical models of inflammatory disease.
View Article and Find Full Text PDFJ Am Soc Mass Spectrom
January 2025
Department of Chemistry, Zhejiang University, Hangzhou, Zhejiang 310027, China.
A novel ionic liquid MALDI matrix, 3-aminoquinoline/2',4',6'-trihydroxyacetophenone monohydrate (3-AQ/THAP), was developed for the rapid qualitative and quantitative detection of miRNA from biological samples. Compared to the traditional matrix 2,5-dihydroxybenzoic acid (DHB) and previously reported oligonucleotide-specific matrices, such as 3-aminopicolinic acid (3-APA), 3-hydroxypicolinic acid (3-HPA), and 6-aza-2-thiothymine (ATT), the 3-AQ/THAP matrix offers several advantages. It produces fewer alkali metal adduct peaks, exhibits higher sensitivity, and ensures better spot-to-spot repeatability.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!